MBX Biosciences, Inc. (NYSE:MBX – Get Free Report) shares gapped up before the market opened on Tuesday . The stock had previously closed at $24.20, but opened at $25.51. MBX Biosciences shares last traded at $24.50, with a volume of 35,933 shares.
Analyst Ratings Changes
MBX has been the subject of several research reports. JPMorgan Chase & Co. assumed coverage on MBX Biosciences in a research report on Tuesday. They issued an “overweight” rating and a $30.00 target price for the company. Guggenheim started coverage on shares of MBX Biosciences in a report on Tuesday. They issued a “buy” rating and a $44.00 price objective for the company. Jefferies Financial Group began coverage on shares of MBX Biosciences in a report on Tuesday. They set a “buy” rating and a $35.00 target price on the stock. Finally, Stifel Nicolaus initiated coverage on shares of MBX Biosciences in a research note on Tuesday. They issued a “buy” rating and a $40.00 price target for the company.
Check Out Our Latest Research Report on MBX
MBX Biosciences Trading Down 5.1 %
Insider Buying and Selling
MBX Biosciences Company Profile
MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.
Featured Stories
- Five stocks we like better than MBX Biosciences
- Stock Average Calculator
- These Stocks Are Using Buybacks to Unlock Big Gains for Investors
- Technology Stocks Explained: Here’s What to Know About Tech
- This Is the Entry Into PepsiCo You’ve Been Waiting For
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- 3 Dividend-Paying Chip Stocks You Don’t Want to Miss
Receive News & Ratings for MBX Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MBX Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.